Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combined Transarterial Chemoembolization, Tyrosine Kinase Inhibitor/ Anti-VEGF Antibody, and Anti-PD-1/ PD-L1 Antibody as Conversion Therapy for Advanced Hepatocellular Carcinoma: a Multicenters, Real-world, Ambispective Cohort Study

NCT05717738 is registered in ClinicalTrials.gov with Tongji Hospital as lead sponsor.

NCT NCT05717738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05717738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combined Transarterial Chemoembolization, Tyrosine Kinase Inhibitor/ Anti-VEGF Antibody, and Anti-PD-1/ PD-L1 Antibody as Conversion Therapy for Advanced Hepatocellular Carcinoma: a Multicenters, Real-world, Ambispective Cohort Study
Lead sponsor
Tongji Hospital
Phase
Observational
Overall status
Unknown status
Start date
January 20, 2022
Completion date
December 31, 2024
Enrollment
300 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma non-resectable